Regarding cytogenetic analysis, 82.5% of AML patients are within the group of the intermediate risk with Normal Karyotype (33 patients) of which 25 showed the highest statistically significant expression of MCL1 (p <0.001), Table 4. Here, MCL1 is linked to acute myeloid leukemia.